IN THE CLAIMS

Please delete claims 1 - 28 without prejudice or disclaimer, and amend claims 29 and 30 as follows:

Claims 1 - 28 (canceled)

Claim 29. (currently amended) A method of using a reversible inhibitor of DPP-IV, comprising administering to a human patient suffering from a central nervous system disorder a pharmaceutically effective amount of the inhibitor, wherein the inhibitor is



wherein R is NH-R^{I};

R^{I} is: C_1 - C_{12} straight or branched chain alkyl;

C_3 - C_7 cycloalkyl;

CH_2- CH_2-NH-R^{II};

CH_2- CH_2-R^{III};

CH_2- CH_2-CHR^{IV}- R^{IV}; or

CH_2- CH_2-CH_2-R^{V};

R^{II} is a pyridine ring optionally substituted in one or two positions with halo, trifluoromethyl, cyano or nitro; or a pyrimidine ring optionally substituted in one position with halo, **[trifluromethyl]** **trifluoromethyl**, cyano or nitro;

R^{III} is a phenyl ring optionally substituted in one to three positions with halo or C_1 - C_3 alkoxy;

Each R^{IV} is independently a phenyl ring optionally substituted in one position with halo or C_1 - C_3 alkoxy; and

R^V is a 2-oxopyrrolidine group or a C_2 - C_4 alkoxy group.

R^{III} is a phenyl ring optionally substituted in one to three positions with halo or C_1 - C_3 alkoxy;

Each R^{IV} is independently a phenyl ring optionally substituted in one position with halo or C_1 - C_3 alkoxy; and

R^V is a 2-oxopyrrolidine group or a C_2 - C_4 alkoxy group.

30. (currently amended) A method of using a reversible inhibitor of DPP-IV, comprising administering to a human patient suffering from a central nervous system disorder a **[pharamceutically]** **pharmaceutically** effective amount of the inhibitor, wherein the inhibitor is



wherein R is NH-R^I;

R^I is: C_1 - C_{12} straight or branched chain alkyl optionally substituted with hydroxy, acetyl, C_1 - C_3 alkoxy, or C_1 - C_3 hydroxyalkyl;

C_3 - C_{12} cycloalkyl optionally substituted with hydroxyl, acetyl, C_1 - C_3 alkoxy, or C_1 - C_3 hydroxyalkyl;

adamantyl; indanyl; piperidyl optionally substituted with benzyl; pyrrolidine optionally substituted with benzyl; bicycloheptyl optionally substituted in one to three positions with methyl; phenyl optionally substituted with in one to three positions with halo, methoxy, trifluoromethyl; pyridyl optionally substituted in one to three positions with halo, trifluoromethyl, nitro; or pyrimidyl optionally substituted with halo, trifluoromethyl, nitro;

C_1 - C_3 straight or branched chain alkyl substituted with RI^{IV} , and optionally substituted with hydroxy; or

$(CH_2)_{1-3}$ - $NR^{II}R^{III}$;

R^{II} is hydrogen or methyl;

R^{III} is phenyl optionally substituted with CN, or pyridyl optionally substituted with CN; and

R^{IV} is a group selected from phenyl, naphthyl, cyclohexenyl, pyridyl, pyrimidyl, adamantyl, phenoxy, wherein the group is optionally substituted in one to two positions with ethoxy, methoxy, halo, phenylsulfside, or phenylsulfide substituted with hydroxymethyl.